Skip to content

Pricing of public offering of common stock

Pricing of public offering of common stock

Feb 12, 2019 MacroGenics Announces Pricing of Public Offering of Common Stock. ROCKVILLE, MD , Feb. 12, 2019 (GLOBE NEWSWIRE) --. MacroGenics  May 22, 2018 Inc. (the "Company") announced today the pricing of an underwritten public offering of 3,333,334 shares of its common stock at a price to the  Jun 19, 2019 In addition, Scholar Rock has granted the underwriters a 30-day option to purchase up to an additional 450,000 shares of common stock. The  Certain of our officers and directors have indicated that they will purchase an aggregate of approximately 18,400 shares of our common stock in this offering at the public offering price.

In addition, Axon has granted the underwriters a 30-day option to purchase up to an additional 645,000 shares of common stock. The gross proceeds to the Company from the offering, before deducting underwriting discounts and estimated offering expenses, are expected to be $212 million,

Jan 23, 2020 the pricing of its underwritten public offering of 8,000,000 shares of its common stock by certain selling shareholders at a public offering price  Jan 10, 2020 EVANSTON, Ill. , Jan. 10, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing 

The closing of the offering is expected to take place on November 26, 2019. The underwriters have an option to purchase up to an additional 750,000 shares of common stock from the Company. Roth Capital Partners and Aegis Capital Corp. are acting as the joint book-running managers for the offering.

Rigel Pharmaceuticals, Inc. SOUTH SAN FRANCISCO, Calif., April 19, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the pricing of its previously announced underwritten public offering of 16,000,000 shares of its common stock, offered at a price of $3.90 per share to the public.

Jan 18, 2020 First, a company goes public with an initial public offering (IPO) of stock. For example, XYZ Inc. has a successful IPO and raises $1 million by 

The closing of the offering is expected to take place on November 26, 2019. The underwriters have an option to purchase up to an additional 750,000 shares of common stock from the Company. Roth Capital Partners and Aegis Capital Corp. are acting as the joint book-running managers for the offering. SAN DIEGO, Jan. 9, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the pricing of an underwritten public offering of 3,076,924 shares of its common stock at a price to the public of $97.50 per share. --Ziopharm Oncology, Inc. today announced the pricing of an underwritten public offering of 27,826,086 shares of its common stock at a public offering price of $3.25 per share. In connection with the Offering, Catalent has granted the underwriters an option for 30 days to purchase up to an additional $75 million of shares of its common stock.

(NASDAQ: AGIO) today announced the pricing of its underwritten public offering of 2,000,000 shares of its common stock at a public offering price of $44.00 per 

Intellia also granted the underwriters a 30-day option to purchase up to an additional 937,500 shares of common stock. The gross proceeds from the offering,  today announced the pricing of its public offering of 4,300,000 shares of its common stock at a price to the public of $21.50 per share. Of the shares of common  (NASDAQ: AGIO) today announced the pricing of its underwritten public offering of 2,000,000 shares of its common stock at a public offering price of $44.00 per  Jun 3, 2019 The underwriters have a 30-day option to purchase up to an additional 1,650,000 shares from the Company at the public offering price. The  Jan 23, 2020 Misonix Announces Pricing of Public Offering of Common Stock shares of its common stock at a price to the public of $18.50 per share. Jan 23, 2020 the pricing of its underwritten public offering of 8,000,000 shares of its common stock by certain selling shareholders at a public offering price  Jan 10, 2020 EVANSTON, Ill. , Jan. 10, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing 

Apex Business WordPress Theme | Designed by Crafthemes